
    
      This study is an open-label pilot study of orally administered RAPA to measure its target
      engagement in Cerebrospinal Fluid (CSF) and blood, and to establish the feasibility and
      safety of RAPA treatment in older adults with MCI and early stage AD as initial
      proof-of-concept for a larger Phase 2 clinical trial.
    
  